Company news

Xencor, Inc. news in 2024

Xencor, Inc.'s news releases, calls and decks from 2024, newest first.

View company

Xencor Reports Third Quarter 2024 Financial Results

November 5, 2024

Xencor Doses First Subject in Phase 1/2 Study of XmAb®942 in Development for Patients with Inflammatory Bowel Disease

November 3, 2024

Xencor Presents Preclinical Data on XmAb942, a High-Potency Extended Half-Life Anti-TL1A Antibody, to be Developed for Patients with Inflammatory Bowel Diseases

October 9, 2024

Xencor Announces Upcoming Change to Board of Directors

October 3, 2024

Xencor Announces Closing of Public Offering Including Full Exercise of Underwriters’ Option to Purchase Additional Shares

September 11, 2024

Xencor Announces Pricing of $175 Million Public Offering of Common Stock

September 10, 2024

Xencor Announces Proposed Public Offering of Common Stock

September 9, 2024

Xencor Announces XmAb Drug Candidates in Autoimmune Disease with Near-Term Clinical Plans and Shares Clinical Progress in Early-Stage Oncology Programs

September 8, 2024

Xencor to Host Research & Development Webcast and Conference Call on Monday, September 9, 2024

September 5, 2024

Xencor Reports Second Quarter 2024 Financial Results

August 4, 2024

Xencor Regains CD20 x CD3 Bispecific T-Cell Engager

June 12, 2024

Xencor Reports First Quarter 2024 Financial Results

May 8, 2024

Xencor Appoints Bart Cornelissen as Chief Financial Officer

April 8, 2024

Xencor to Present at Upcoming Investor Conferences

February 27, 2024

Xencor Reports Fourth Quarter and Full Year 2023 Financial Results

February 26, 2024

Xencor to Host Webcast to Review Fourth Quarter and Full Year 2023 Financial Results and Provide Vudalimab Clinical Update

February 19, 2024

Xencor to Present at the 42nd Annual J.P. Morgan Healthcare Conference

January 2, 2024

Dane Leone Joins Xencor as Senior Vice President, Corporate Strategy

January 1, 2024

Calls in 2024

Decks in 2024